




Welcome to the first edition of the new SACT newsletter. We aim to release the newsletter at regular intervals in order to keep SACT colleagues up to date with any developments or new communications.

## CancerStats2



As most of you will now be aware, SACT data is now available on CancerStats2. You can find the most recent reports on [cancerstats.ndrs.nhs.uk/user/login](http://cancerstats.ndrs.nhs.uk/user/login)

The reports that are currently available to registered users with an N3 connection are:

### ► MO CQUIN compliance reports

We published these reports to support trusts in understanding their compliance for the MO CQUIN for 2017/18 financial year. We will continue to produce these reports to help support trusts in improving their SACT data and meet the requirements of the NHSE standard contract.

### ► Dose banding reports

This brand new report presents drug administration inside and outside national dose bands from January 2015 to present. The report allows users to evaluate overall trust performance and trends at a drug level. Users can assess their own performance comparison to other trusts at a regional and national level.

## Soon to be released

### ► Children, teenager and young adults (CTYA) reports

(September 2018)

Please contact [Stephen.benson@phe.gov.uk](mailto:Stephen.benson@phe.gov.uk) with questions or feedback.

### ► CDF reports (September 2018)

► Trust reporting suite (activity reports; previously sent as a PDF) (September 2018)

To register for CancerStats2 please follow the link below:

[cancerstats.ndrs.nhs.uk/user/register](http://cancerstats.ndrs.nhs.uk/user/register)

Please continue to offer feedback on reports and let the helpdesk know if you have any specific requests for the team to consider.

## SACT Helpdesk update

### SACT portal

In June 2018, we introduced a new SACT portal for trusts to submit their monthly data uploads. This new portal now allows SACT data to feed directly into the NCRAS main data management system, known as ENCORE. From here, the data can be linked with other cancer datasets. If you are experiencing any issues and require assistance with the new portal please contact the helpdesk: [SACT@phe.gov.uk](mailto:SACT@phe.gov.uk)

### New portal:

[www.api.encore.nhs.uk/users/sign\\_in](http://www.api.encore.nhs.uk/users/sign_in)

### Deadlines

- We have removed the approval step from the portal and trusts now have the full month to upload their file.
- Your trusts deadline for upload is now the last day of the month, not the 15th. Please do not leave uploading to the last day of the month as this will not allow enough time to fix errors.
- Regimen mapping must be completed by the 15th of the second month following upload
- Regimen queries must be resolved and the file must be submitted by the end of the second month.

Further training on the new portal, as well as upload schedule examples, can be found on our website [www.chemodataset.nhs.uk](http://www.chemodataset.nhs.uk)

### Regimen mapping

Please note that you need to complete all your regimen mapping on a file before you can submit it to the portal. You can do your mapping on the portal, using the regimen map button. This tends to be a quick and easy task and is usually done by a trust pharmacist.

We are on hand to help with any queries or challenges, just get in

## Data Liaison Update

The data liaison team are on hand to visit trusts and offer support with the SACT dataset. If you would like a visit from the team please contact one of our data liaison officers:

Nicola Ace ([Nicola.ace@phe.gov.uk](mailto:Nicola.ace@phe.gov.uk))

Priscilla Thiruchelvam ([Priscilla.Thiruchelvam@phe.gov.uk](mailto:Priscilla.Thiruchelvam@phe.gov.uk))

Stephen Benson ([Stephen.benson@phe.gov.uk](mailto:Stephen.benson@phe.gov.uk))

### User Forum

Nicola is in the process of developing a forum for trusts to use as a platform for contacting other trusts. This tool can be used to discuss any SACT issues, share best practice and feedback to the SACT team. This is due to go live in early October but please contact [Nicola](#) if you are happy to be involved in the initial testing phase. We want this to benefit trusts as much as possible so we rely on your input and feedback to make this happen. Please note, access to the SACT forum will only be available for staff working within NHS hospitals.


touch via the 'request help' button on the portal or by emailing [SACT@phe.gov.uk](mailto:SACT@phe.gov.uk)

### Outcomes report

We are in the process of developing the portal to accept a smaller extract containing patient outcomes. We hope this will help users to submit their outcome data. We have been working with the e-prescribing systems to develop this function. If your trusts would like to help pilot this extract, please email [SACT@phe.gov.uk](mailto:SACT@phe.gov.uk)

## SACT dataset review

Public Health England reviewed the SACT dataset to ensure it remains fit for purpose and submitted a revised draft dataset to NHS Digital in July 2018. Once approved, the updated dataset will become the new SACT dataset standard for expected release in autumn 2019. We included input and feedback from a range of people involved in collecting, analysing and using the data, such as NHS provider trusts, pharmacists, clinicians, analysts and commissioners. Overall, stakeholders agreed that the current dataset works in practice but its collection and use can be improved with some simple updates to definitions, increasing available response options and removing certain items that are already collected in other PHE datasets. We are working to the following timeline:



## SACT analysis

Our team of analysts are continuing to use the data you submit to produce meaningful and useful publications. They are currently working on a number of projects which includes a new report on 30 day mortality post SACT.

### 30-day mortality reports

We previously used SACT data to publish 30-day post-SACT mortality analyses for breast and lung cancer across all NHS trusts in England. This study was the first of its kind, using routinely collected data to look at patient outcomes by trust and for England. We hope that analyses such as these can support clinical decision making and potentially improve outcomes for cancer patients.

Follow [bit.ly/2bRaUqY](http://bit.ly/2bRaUqY) to access the report.

We are currently working on piloting an approach to calculate and share crude 30 day mortality post SACT for a range of tumour types, on a regular basis. This will include information by trust and for England overall.

## The Cancer Drugs Fund (CDF)

**NICE** National Institute for Health and Care Excellence

As some of you will already be aware, the SACT team works very closely with the National Institute for Health and Care Excellence (NICE) in appraising all new CDF treatments. For that reason, the SACT dataset requires all CDF treatments to be included in monthly SACT uploads and for the data to be correct and complete as possible. Trusts are also required to include the outcome of the treatment (when appropriate) in their SACT uploads. The list of drugs currently available through the CDF can be found on the [NICE website](#).

The data liaison team will continue to contact trusts who have missing SACT data for CDF patients to ensure all data is collected. Data completeness reports for these patients will also be available on CancerStats2 in due course.

More details to follow as we start sharing this data.

## Important Links

### New portal registration—

[www.cancerstats.nhs.uk/users/sign\\_up](http://www.cancerstats.nhs.uk/users/sign_up)

### New portal access—

[www.api.encore.nhs.uk/users/sign\\_in](http://www.api.encore.nhs.uk/users/sign_in)

### CancerStats2 registration—

[cancerstats.ndrs.nhs.uk/user/register](http://cancerstats.ndrs.nhs.uk/user/register)

### CancerStats2 report access—

[cancerstats.ndrs.nhs.uk/](http://cancerstats.ndrs.nhs.uk/)

## Brentuximab

Towards the end of 2017, the SACT team distributed a large number of questionnaires for clinicians to complete regarding previous brentuximab treatments. The completion rate for these questionnaires was a **fantastic 89%** - thank you everyone for your support. The results played a crucial role in the appraisal of the drug which has now been recommended in the NICE committee appraisal for routine funding through the NHS.

You can find more information on this drug's appraisal on [www.nice.org.uk/guidance/ta524](http://www.nice.org.uk/guidance/ta524)

*As always we welcome your feedback. Please send any comments and suggestions for future*

*newsletters to the SACT helpdesk [SACT@phe.gov.uk](mailto:SACT@phe.gov.uk)*

You have been sent this newsletter because you have previously expressed an interest in the SACT dataset. If you are happy to continue to receive this newsletter you do not need to do anything. If you do not wish to receive future SACT newsletters please email [SACT@phe.gov.uk](mailto:SACT@phe.gov.uk) and let us know if you want to be removed from the newsletter circulation list and/or SACT communications more broadly. Alternatively you can click the unsubscribe button below.